Bristol Myers Squibb’s Post

John Mascarenhas, MD, shares insight into his study regarding the addition of pelabresib to a medication known as ruxolitinib in order to improve outcomes and quality of life in patients with myelofibrosis. #Myelofibrosis #MedicalResearch #TreatmentStudy https://lnkd.in/eR2x8j4s

Clinical trials are not a last resort. Clinical trial participation can be beneficial at any point in your diagnostic and treatment path. Getting connected to a clinical trial at diagnosis may mean you have even more treatment options, as some trial eligibility can be limited by how many treatments you have received already.  Learn more about clinical trials at https://lnkd.in/eMbQcWR8  #colorectalcancer #clinicaltrials #cancertreatment #coloncancer #rectalcancer

Let's start talking about #CKD with the same urgency that we talk about hypertension, heart disease, and even cancer. With CKD impacting more than 1/10 of people worldwide, chances are someone you know will be affected. Empowering patients with knowledge, particularly understanding kidney function tests and their results, can enable them to actively participate in decisions regarding their care. The following article presents an overview of the tests commonly used to diagnose CKD in clinical practice, as well as actionable suggestions for patients, clinicians, and health policymakers that could help improve disease detection and treatment. Learn how to start the conversation here: https://bit.ly/4acreeN #KidneyHealth #ChronicKidneyDisease #HealthcareAwareness #EmpowerPatients

AUSTRALIAN HEALTH AUTHORITIES & POLICY MAKERS PLEASE TAKE NOTE: "American Society of Interventional Pain Physicians have [now] released new pain guideline[s] for opioid use in non-cancer pain. This guideline suggest[s] that chronic opioid therapy BE PROVIDED IN LOW DOSES with appropriate adherence monitoring and understanding of adverse events in patients with a proven medical necessity, and show a stable improvement in both pain relief and activities of daily function, either independently or in conjunction with other modalities of treatment." Recent TGA Australian Opioid Prescribing Guideline changes [2020 & 2023], have led to involuntary deprescribing & force-tapering of opioids from many sick & disabled Australians, using their legally prescribed painkillers appropriately under medical supervision. These harmful practices should NOT be allowed under any circumstances. WHY? Because chronic pain patients did NOT cause a "prescription" opioid crisis in our country or America! #America #Australia #painrelief #forcedtapers #chronicsecondarypain #severedisablingpain #persistentpain #opioidguidelines #deprescribing #chronicpainmanagement #noonesizefitsall #patientadvocacy #multidisciplinarycare #selfmanagement #medicalgaslighting #tga #undertreatedpain #prescriptionopioids #opioidcrisis #opioidepidemic #addiction #dependence #overdose #polypharmacy #opioidrestrictions #opiophobia #opioidhysteria #substanceabuse #opioidusedisorder #holisticcare #qualityoflife #humanrights #education #stopthestigma

For the first time, an AI-designed drug is heading into Phase II of clinical trials. This groundbreaking medication targets idiopathic pulmonary fibrosis, a debilitating lung disease.  Utilizing artificial intelligence, the drug was fast-tracked from discovery to Phase I trials in record time, showing promising results in reducing lung scarring. Now, with Phase II trials underway, we're one step closer to a potential breakthrough in treating this deadly condition. Stay tuned for updates! #AIDesignedDrug #MedTech #MedicalInnovation #HealthcareTechnology #DigiFacts

In the #KENDO trial, there was no benefit from using 1L/2L #chemo vs. #CDKinhibitor + endocrine therapy in chemo-naïve patients with aggressive HR+/HER2– metastatic #BreastCancer. #CD24 was significantly associated with worse PFS in both arms. #bcsm https://lnkd.in/emgcnHcN

Today we are focusing on the TREAT component of our Learn- Treat - Cure initiative for our science and research strategy. To TREAT the disorder, the Dup15 Alliance will promote and support research that informs strategies to improve patient quality of life through symptom management and elimination. Trial Updates: This month, Takeda shared Topline data from the SKYWAY phase 3 studies assessing soticlestat in patients with Lennox-Gastaut syndrome (LGS). The drug narrowly missed its primary endpoint of reduction in Major Motor Drop (MMD) seizure frequency as compared with placebo in patients with refractory LGS. Next steps for enrolled individuals are actively evolving. In brighter news, Longboard released a positive interim analysis of the PACIFIC study’s Open Label Extension (OLE) earlier this month. Bexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treatment period. Participants randomized to the PACIFIC placebo group achieved a median seizure reduction of 57.3%, with favorable safety and tolerability results observed. Excitingly,100% of participants who completed the PACIFIC Study entered the OLE. Stay tuned for upcoming information on the upcoming phase 3 program!

Learn more about clinical trials in Europe for myeloma and AL amyloidosis patients by using our Navigator tool. You can find trials matching your criteria, from specific hospitals to disease stages. Explore the MPE Navigator now: https://lnkd.in/dDRHsv2Z #ClinicalTrials #Research #myeloma #ALAmyloidosis

MEDCast Update! Paul Hahn, Jennifer Lim and Michael Cohen discuss Faricimab Versus High-Dose Aflibercept for the Treatment of Neovascular AMD and DME So many hot topics in VEGF and ANG-2 treatment of retinal disease!

May is #LupusAwarenessMonth – and today is #WorldLupusDay! Lupus affects millions of people, so today and always, let’s show our love and support for all in the Lupus community; including our Members, who work tirelessly to bring the best care to their Lupus patients. Lupus affects each person differently, often with different symptoms. More research is needed to help find treatments, and ultimately, a cure. Specialty Networks encourages you to take time to shine light on lupus, honor every lupus champion, and celebrate all who are making a difference in the Lupus community. This past January, PPS Analytics (A Specialty Networks Company) expanded to Rheumatology. PPS is an AI-enabled technology designed to help our members identify, navigate, and engage patients to improve adherence to clinical care pathways and protocols for diagnostics and therapeutic intervention with over 21,000 active Lupus patients on the platform...and growing. Learn more: https://lnkd.in/eRYg3uty